COPÉRNICO

COPERNICO PRIMARY OBJECTIVE IS TO ASSESS THE EFFICACY–AS DETERMINED BY THE PROPORTION OF PATIENTS WITH NORMALIZATION OF SPO2 ≥96%– OF CONTINUED STANDARD CARE TOGETHER WITH TOCILIZUMAB PLUS PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH COVID-19 PNEUMONIA WHO ARE NONRESPONSIVE TO FRONTLINE THERAPY WITHIN 48 HOURS FROM TREATMENT INITIATION.

EXPLORATORY OBJECTIVE IS TO ESTABLISH WHETHER STUDY TREATMENT WOULD ALLOW TO RECOVER T CELL FUNCTIONALITY AND REGULATE CYTOKINE STORM IN PATIENTS WITH COVID-19 PNEUMONIA WHO ARE NONRESPONSIVE TO FRONTLINE THERAPY WITHIN 48 HOURS FROM TREATMENT INITIATION.